<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Tolcapone</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Tolcapone">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Tolcapone</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Tolcapone</b> (brand name <b>Tasmar</b>) is a drug used to treat Parkinson's disease (PD).  It is a selective, potent and reversible nitrocatechol-type inhibitor of the enzyme catechol-<i>O</i>-methyltransferase (COMT).<span class="mw-ref" id="cite_ref-pmid18728767_1-0"><a href="#cite_note-pmid18728767-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> It has demonstrated significant liver toxicity, which has led to suspension of marketing authorisations in a number of countries.</p>


<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Tolcapone</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/Tolcapone.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Tolcapone.svg.png" data-file-width="512" data-file-height="350" data-file-type="drawing" height="150" width="220"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/Tolcapone3d.png" tppabs="https://ptable.com/wiki/compounds/I/m/Tolcapone3d.png" data-file-width="752" data-file-height="467" data-file-type="bitmap" height="137" width="220"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Tasmar</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/tolcapone.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/tolcapone.html'" tppabs="https://www.drugs.com/monograph/tolcapone.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a698036.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a698036.html'" tppabs="https://medlineplus.gov/druginfo/meds/a698036.html" class="external text external">a698036</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Tolcapone  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Tolcapone'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Tolcapone" class="external text external">by INN</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr>:</small><span> </span>C (Risk not ruled out)<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>By mouth</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>N04BX01<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=N04BX01  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=N04BX01'" tppabs="https://www.whocc.no/atc_ddd_index/?code=N04BX01" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">UK</abbr>:</small><span> </span>POM (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>65%</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>&gt;99.9%</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Hepatic (mainly glucuronidation)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>2–3 hours</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>Urine (60%), faeces (40%);<br>only 0.5% in unmetabolised form</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">(3,4-Dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=134308-13-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=134308-13-7'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=134308-13-7" class="external text external">134308-13-7</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/4659569  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/4659569'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/4659569" class="external text external">4659569</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6646  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6646'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6646" class="external text external">6646</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00323  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00323'" tppabs="https://www.drugbank.ca/drugs/DB00323" class="external text external">DB00323</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.3848682.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.3848682.html'" tppabs="http://www.chemspider.com/Chemical-Structure.3848682.html" class="external text external">3848682</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=CIF6334OLY  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=CIF6334OLY'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=CIF6334OLY" class="external text external">CIF6334OLY</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D00786  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D00786'" tppabs="https://www.kegg.jp/entry/D00786" class="external text external">D00786</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1324  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1324'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1324" class="external text external">ChEMBL1324</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID3023685  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID3023685'" tppabs="https://comptox.epa.gov/dashboard/DTXSID3023685" class="external text external">DTXSID3023685</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.222.604  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.222.604'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.222.604" class="external text external">100.222.604</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>14</sub><span>H</span><sub>11</sub><span>N</span><span>O</span><sub>5</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">273.244</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=%5BO-%5D%5BN%2B%5D%28%3DO%29c2cc%28C%28%3DO%29c1ccc%28cc1%29C%29cc%28O%29c2O  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=%5BO-%5D%5BN%2B%5D%28%3DO%29c2cc%28C%28%3DO%29c1ccc%28cc1%29C%29cc%28O%29c2O'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=%5BO-%5D%5BN%2B%5D%28%3DO%29c2cc%28C%28%3DO%29c1ccc%28cc1%29C%29cc%28O%29c2O" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Melting point</th><td>143 to 146<span>&nbsp;</span>°C (289 to 295<span>&nbsp;</span>°F)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Solubility in water</th><td>not soluble</td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">[O-][N+](=O)c2cc(C(=O)c1ccc(cc1)C)cc(O)c2O</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:MIQPIUSUKVNLNT-UHFFFAOYSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=470611468&page2=Tolcapone  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=470611468&page2=Tolcapone'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=470611468&page2=Tolcapone" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>In comparison with <a href="Entacapone.htm" tppabs="https://ptable.com/wiki/compounds/A/Entacapone" title="Entacapone">entacapone</a>, another nitrocatechol COMT inhibitor, tolcapone has a longer half life (2.9 hours vs. 0.8 hours) and can better penetrate the blood–brain barrier, acting both in the central nervous system and in the periphery.<span class="mw-ref" id="cite_ref-2"><a href="#cite_note-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> However, entacapone is less toxic for the liver.</p>
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/3s68_tcw.png" tppabs="https://ptable.com/wiki/compounds/I/m/3s68_tcw.png" data-file-width="600" data-file-height="600" data-file-type="bitmap" height="220" width="220"><div class="thumbcaption" style="text-align: left">Rat catechol-<i>O</i>-methyltransferase bound to tolcapone. PDB entry <span class=""><a href="javascript:if(confirm('https://www.ebi.ac.uk/pdbe/entry/pdb/3s68  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/pdbe/entry/pdb/3s68'" tppabs="https://www.ebi.ac.uk/pdbe/entry/pdb/3s68" class="external text external">3s68</a></span><span class="mw-ref" id="cite_ref-3"><a href="#cite_note-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></div></div></div>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    
<p>Tolcapone is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa or levodopa/benserazide medications. Levodopa is a prodrug for <a href="Dopamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dopamine" title="Dopamine">dopamine</a>, which reduces Parkinson symptoms; <a href="Carbidopa.htm" tppabs="https://ptable.com/wiki/compounds/A/Carbidopa" title="Carbidopa">carbidopa</a> and benserazide are aromatic <small>L</small>-amino acid decarboxylase (AADC) inhibitors.<span class="mw-ref" id="cite_ref-4"><a href="#cite_note-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>

<p>Without administration of tolcapone, the beneficial effects of levodopa tend to wear off more quickly, resulting in motor fluctuations.<span class="mw-ref" id="cite_ref-ncbi_a_5-0"><a href="#cite_note-ncbi_a-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Contraindications">Contraindications</h2></summary>
    
<p>Combining tolcapone with non-selective monoamine oxidase inhibitors such as <a href="Phenelzine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenelzine" title="Phenelzine">phenelzine</a> or <a href="Tranylcypromine.htm" tppabs="https://ptable.com/wiki/compounds/A/Tranylcypromine" title="Tranylcypromine">tranylcypromine</a> is contraindicated.<span class="mw-ref" id="cite_ref-Dinnendahl_6-0"><a href="#cite_note-Dinnendahl-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> Tolcapone is also contraindicated for people with liver diseases or increased liver enzymes.<span class="mw-ref" id="cite_ref-EMA_7-0"><a href="#cite_note-EMA-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Side_effects">Side effects</h2></summary>
    
<p>Tolcapone has demonstrated significant liver toxicity (hepatotoxicity)<span class="mw-ref" id="cite_ref-pmid17909307_8-0"><a href="#cite_note-pmid17909307-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> that limits the drug's utility. <a href="Entacapone.htm" tppabs="https://ptable.com/wiki/compounds/A/Entacapone" title="Entacapone">Entacapone</a> is an alternative, largely since it has a more favorable toxicity profile.</p>

<p>The hepatotoxicity can be related to elevated levels of transaminases, but studies have shown that minimal risk exists for those without preexisting liver conditions when their enzyme levels were being monitored. No clear mechanism is implicated, but it has been hypothesized that it has something to do with abnormal mitochondrial respiration due to the uncoupling of oxidative phosphorylation.<span class="mw-ref" id="cite_ref-ncbi_b_9-0"><a href="#cite_note-ncbi_b-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p> 

<p>Other side effects regard the increase in dopaminergic activity, including digestive symptoms.<span class="mw-ref" id="cite_ref-EMA_7-1"><a href="#cite_note-EMA-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> Treatment with tolcapone runs the risk of eliciting or prolonging dyskinesia; this can be counteracted by decreasing the dose of levodopa. This occurs because the administration of tolcapone results in the accumulation of the biological methyl donor <a href="S-Adenosyl_methionine.htm" tppabs="https://ptable.com/wiki/compounds/A/S-Adenosyl_methionine" title="S-Adenosyl methionine"><i>S</i>-adenosyl-<small>L</small>-methionine</a> (SAM) in the striatum that induces Parkinson symptoms.<span class="mw-ref" id="cite_ref-ncbi_b_9-1"><a href="#cite_note-ncbi_b-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>

<p>Digestive symptoms include nausea and diarrhea; further dopaminergic side effects include orthostatic hypotension, dry mouth, sweating and dizziness.  Tolcapone causes more severe diarrhea than entacapone; this was the most common reason for therapy termination in studies.<span class="mw-ref" id="cite_ref-Dinnendahl_6-1"><a href="#cite_note-Dinnendahl-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> Urine discoloration comes from yellow tolcapone metabolites being excreted in the urine and is harmless.<span class="mw-ref" id="cite_ref-EMA_7-2"><a href="#cite_note-EMA-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-ncbi_b_9-2"><a href="#cite_note-ncbi_b-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Interactions">Interactions</h2></summary>
    
<p>While increase of dopamine levels is a desired interaction, tolcapone can theoretically also increase the levels of other drugs metabolised by COMT, such as the AADC inhibitors carbidopa and benzerazide, as well as <a href="Methyldopa.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyldopa" title="Methyldopa">methyldopa</a>, <a href="Dobutamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dobutamine" title="Dobutamine">dobutamine</a>, <a href="Apomorphine.htm" tppabs="https://ptable.com/wiki/compounds/A/Apomorphine" title="Apomorphine">apomorphine</a>, adrenaline, and <a href="Isoprenaline.htm" tppabs="https://ptable.com/wiki/compounds/A/Isoprenaline" title="Isoprenaline">isoprenaline</a>. In studies, a slight interaction with benzerazide was seen, but not with carbidopa. Other interactions with this group of drugs have not been studied. A related type of theoretical interactions is with drugs that increase catecholamine concentrations, such as monoamine oxidase (MAO) inhibitors and noradrenaline reuptake inhibitors; these also showed only slight effects in practice. Combination with <i>non-selective</i> MAO inhibitors might be dangerous.<span class="mw-ref" id="cite_ref-Dinnendahl_6-2"><a href="#cite_note-Dinnendahl-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-EMA_7-3"><a href="#cite_note-EMA-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>

<p>Due to its affinity to the liver enzyme CYP2C9, interactions with drugs being metabolised by this enzyme are also possible, but unlikely. No interaction with <a href="Tolbutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Tolbutamide" title="Tolbutamide">tolbutamide</a>, a 2C9 substrate, was observed in studies.<span class="mw-ref" id="cite_ref-EMA_7-4"><a href="#cite_note-EMA-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacology">Pharmacology</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Mechanism_of_action">Mechanism of action</h3></summary>
    
<p>Tolcapone selectively and reversibly<span class="mw-ref" id="cite_ref-Dinnendahl_6-3"><a href="#cite_note-Dinnendahl-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> binds to the catalytic site of COMT in both the periphery and the central nervous system (CNS) with greater affinity than any of the three catecholamines, including levodopa.<span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> It thereby prevents the 3-<i>O</i>-methylation of levodopa by COMT in the periphery, which produces 3-<i>O</i>-methyldopa, a major metabolite that competes with levodopa to cross the blood–brain barrier. More of the levodopa that is administered reaches the CNS. Additionally, levodopa that has already reached the CNS, after being converted to dopamine, will not be degraded as quickly when tolcapone inhibits COMT activity. Thus, tolcapone improves the bioavailability and reduces the clearance of levodopa and subsequently dopamine from the CNS.<span class="mw-ref" id="cite_ref-ncbi_11-0"><a href="#cite_note-ncbi-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>

<center><div class="thumb tnone"></div><div class="thumbinner" style="width:402px"><img src="../I/m/COMT_activity.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/COMT_activity.svg.png" data-file-width="512" data-file-height="134" data-file-type="drawing" height="105" width="400"><div class="thumbcaption" style="text-align: left">3-<i>O</i>-Methylation of levodopa (3-hydroxy-<small>L</small>-tyrosine) via COMT activity</div></div></center>

<p>The strength of the binding affinity of tolcapone, represented by the inhibition constant K<sub>i</sub> (2.5 nM), can be thought of as the dissociation constant for enzyme and inhibitor complex kinetics. Maximum catalytic activity denotes the efficacy of tolcapone (V<sub>max</sub> = 58.4 pmol/min·mg).<span class="mw-ref" id="cite_ref-12"><a href="#cite_note-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacokinetics">Pharmacokinetics</h3></summary>
    
<p>Tolcapone is quickly absorbed from the gut to about 85%. It has an absolute bioavailability of 65%, which is only slightly decreased when taken with food. The substance reaches highest blood plasma concentrations after about two hours. When in the bloodstream, it is almost completely (&gt;99.9%) bound to plasma proteins, primarily albumin. The main inactivation step is glucuronidation; other processes are methylation by COMT, hydroxylation by CYP3A4 and CYP2A6 with subsequent oxidation to a carboxylic acid, and possibly a minor path with reduction to an amine with subsequent acetylation.<span class="mw-ref" id="cite_ref-Dinnendahl_6-4"><a href="#cite_note-Dinnendahl-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-EMA_7-5"><a href="#cite_note-EMA-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>

<p>The half-life of tolcapone is two to three hours, the volume of distribution (V<sub>d</sub>) being 0.3<span>&nbsp;</span>L/kg (21 L in an average 70<span>&nbsp;</span>kg person).<span class="mw-ref" id="cite_ref-ncbi_a_5-1"><a href="#cite_note-ncbi_a-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> 60% of the metabolites are excreted via the urine and 40% via the feces. Only 0.5% of the drug are excreted in unchanged form via the urine.<span class="mw-ref" id="cite_ref-Dinnendahl_6-5"><a href="#cite_note-Dinnendahl-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-EMA_7-6"><a href="#cite_note-EMA-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>

<center><div class="thumb tnone"></div><div class="thumbinner" style="width:602px"><img src="../I/m/Tolcapone_metabolism.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Tolcapone_metabolism.svg.png" data-file-width="1574" data-file-height="927" data-file-type="drawing" height="353" width="600"><div class="thumbcaption" style="text-align: left">Tolcapone and its metabolites. The reduction to the amine and subsequent <i>N</i>-acetylation is putative.<span class="mw-ref" id="cite_ref-EMA_7-7"><a href="#cite_note-EMA-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></div></div></center>

<p>99% of tolcapone is in monoanionic form in the body because the physiological pH is 7.4. Tolcapone penetrates the blood–brain barrier much better than two other nitrocatechols, <a href="Nitecapone.htm" tppabs="https://ptable.com/wiki/compounds/A/Nitecapone" title="Nitecapone">nitecapone</a> and <a href="Entacapone.htm" tppabs="https://ptable.com/wiki/compounds/A/Entacapone" title="Entacapone">entacapone</a>, because it has higher lipophilicity due to its R-substituent. Partition coefficients quantify the ability of the molecule to cross the blood–brain barrier. LogPIdce= 0.2, –1.4, –0.4 for tolcapone, nitecapone and entacopone respectively.  Partition coefficients in this case were measured in 1,2-dichloroethane/H<sub>2</sub>O solution which caused molecules to be in ionized form. There is no current explanation for how these charged molecules permeate the blood–brain barrier.<span class="mw-ref" id="cite_ref-13"><a href="#cite_note-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Chemistry">Chemistry</h2></summary>
    
<p>Tolcapone is an intensely yellow, odorless, bitter tasting, non-hygroscopic, crystalline compound with a relative molecular mass of 273.25<span>&nbsp;</span>g/mol. It melts at <span>143 to 146</span><span>&nbsp;</span><span>°C (289 to 295</span><span>&nbsp;</span><span>°F)</span>, is practically insoluble in water and acids but soluble in 0.1<span>&nbsp;</span>M aqueous sodium hydroxide solution. The p<i>K</i><sub>a</sub> values are 4.5 and 10.6 for the two phenyl groups; and the maximum absorption is at 268<span>&nbsp;</span>nm (in 0.1<span>&nbsp;</span>M hydrochloric acid / ethanol).<span class="mw-ref" id="cite_ref-Dinnendahl_6-6"><a href="#cite_note-Dinnendahl-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> Its chemical name is 3,4-dihydroxy-4'-methyl-5-nitrobenzophenone.</p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Synthesis">Synthesis</h3></summary>
    
<p>A synthesis of tolcapone proposed in 2008 begins with a <a href="Grignard_reaction.htm" tppabs="https://ptable.com/wiki/compounds/A/Grignard_reaction" title="Grignard reaction">Grignard reaction</a> between a benzaldehyde derivative and <i>p</i>-tolyl magnesium bromide. The alcohol thus produced is then converted to a ketone using sodium <i>t</i>-butoxide. The benzyl protecting group is removed by <a href="Palladium.htm" tppabs="https://ptable.com/wiki/compounds/A/Palladium" title="Palladium">palladium</a>-catalyzed hydrogenation in the presence of ammonium formate. A nitro group is introduced at the 5-position adjacent to the hydroxyl group unmasked in the cleavage of the benzyl ether. The synthesis ends with cleavage of the methoxy group using aluminum chloride to yield the product alcohol.<span class="mw-ref" id="cite_ref-Manikumar_14-0"><a href="#cite_note-Manikumar-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></p>

<center><div class="thumb tnone"></div><div class="thumbinner" style="width:602px"><img src="../I/m/Tolcapone_synthesis.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Tolcapone_synthesis.svg.png" data-file-width="512" data-file-height="297" data-file-type="drawing" height="348" width="600"><div class="thumbcaption" style="text-align: left">Synthesis of tolcapone<span class="mw-ref" id="cite_ref-Manikumar_14-1"><a href="#cite_note-Manikumar-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></div></div></center><div style="clear:both;"></div>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>Tolcapone was introduced into European market in August 1997 and subsequently into the United States market in March 1998. Liver toxicity was reported in four people who were administered tolcapone, three people died due to complications.  Consequentially, the marketing authorization of tolcapone was suspended from December, 1998 until August, 2004 when it was lifted. In November 1998, the company that manufactured tolcapone voluntarily<span class="mw-ref" id="cite_ref-apps_15-0"><a href="#cite_note-apps-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span>  removed the drug from the market. The authorization was then renewed in August 2009.<span class="mw-ref" id="cite_ref-EMEA/474722/2009_16-0"><a href="#cite_note-EMEA/474722/2009-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span></p>

<p>As a result of reported complications, the U.S. Food and Drug Administration (FDA) issued a black box warning for tolcapone and label revisions that aimed to regulate the monitoring of those prescribed tolcapone for Parkinson's disease in November 1998.<span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span> A number of other countries withdrew tolcapone from the market; Australia in February 1999, Bulgaria in April 1999, Iceland in November 1998, Lithuania in December 1998.<span class="mw-ref" id="cite_ref-apps_15-1"><a href="#cite_note-apps-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    
<p>Because of preliminary data suggesting the drug may have activity, the U.S. FDA has granted tolcapone "orphan drug status" in studies aiming at the treatment of familial transthyretin amyloidosis (ATTR). However, tolcapone is not FDA approved for the treatment of this disease. <span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span><span class="mw-ref" id="cite_ref-19"><a href="#cite_note-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-pmid18728767-1"> <span id="mw-reference-text-cite_note-pmid18728767-1" class="mw-reference-text"><cite id="CITEREFAntoniniAbbruzzeseBaroneBonuccelli2008" class="citation journal cs1">Antonini A, Abbruzzese G, Barone P, Bonuccelli U, Lopiano L, Onofrj M,  et al. (February 2008). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515921  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515921'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515921" class="external text external">"COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features"</a>. <i>Neuropsychiatric Disease and Treatment</i>. <b>4</b> (1): 1–9. doi:<a href="javascript:if(confirm('https://doi.org/10.2147%2FNDT.S2404  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2147%2FNDT.S2404'" tppabs="https://doi.org/10.2147%2FNDT.S2404" class="external text external">10.2147/NDT.S2404</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515921  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515921'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515921" class="external text external">2515921</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18728767  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18728767'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18728767" class="external text external">18728767</a>.</cite></span></li><li id="cite_note-2"> <span id="mw-reference-text-cite_note-2" class="mw-reference-text"><cite id="CITEREFForsbergLehtonenHeikkinenSavolainen2003" class="citation journal cs1">Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Järvinen T, Männistö PT (February 2003). "Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat". <i>The Journal of Pharmacology and Experimental Therapeutics</i>. <b>304</b> (2): 498–506. doi:<a href="javascript:if(confirm('https://doi.org/10.1124%2Fjpet.102.042846  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1124%2Fjpet.102.042846'" tppabs="https://doi.org/10.1124%2Fjpet.102.042846" class="external text external">10.1124/jpet.102.042846</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12538800  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12538800'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12538800" class="external text external">12538800</a>.</cite></span></li><li id="cite_note-3"> <span id="mw-reference-text-cite_note-3" class="mw-reference-text"><cite id="CITEREFEllermannLernerBurgyEhler2012" class="citation journal cs1">Ellermann M, Lerner C, Burgy G, Ehler A, Bissantz C, Jakob-Roetne R,  et al. (March 2012). "Catechol-O-methyltransferase in complex with substituted 3'-deoxyribose bisubstrate inhibitors". <i>Acta Crystallographica. Section D, Biological Crystallography</i>. <b>68</b> (Pt 3): 253–60. doi:<a href="javascript:if(confirm('https://doi.org/10.1107%2FS0907444912001138  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1107%2FS0907444912001138'" tppabs="https://doi.org/10.1107%2FS0907444912001138" class="external text external">10.1107/S0907444912001138</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22349227  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22349227'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22349227" class="external text external">22349227</a>.</cite></span></li><li id="cite_note-4"> <span id="mw-reference-text-cite_note-4" class="mw-reference-text"><cite id="CITEREFDingemanseJorgaZürcherSchmitt1995" class="citation journal cs1">Dingemanse J, Jorga K, Zürcher G, Schmitt M, Sedek G, Da Prada M, Van Brummelen P (September 1995). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1365105  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1365105'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1365105" class="external text external">"Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa"</a>. <i>British Journal of Clinical Pharmacology</i>. <b>40</b> (3): 253–62. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-2125.1995.tb05781.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-2125.1995.tb05781.x'" tppabs="https://doi.org/10.1111%2Fj.1365-2125.1995.tb05781.x" class="external text external">10.1111/j.1365-2125.1995.tb05781.x</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1365105  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1365105'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1365105" class="external text external">1365105</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8527287  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8527287'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8527287" class="external text external">8527287</a>.</cite></span></li><li id="cite_note-ncbi_a-5"> <span id="mw-reference-text-cite_note-ncbi_a-5" class="mw-reference-text"><cite id="CITEREFJorgaFottelerHeizmannZürcher1998" class="citation journal cs1">Jorga KM, Fotteler B, Heizmann P, Zürcher G (July 1998). "Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy". <i>European Journal of Clinical Pharmacology</i>. <b>54</b> (5): 443–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs002280050490  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs002280050490'" tppabs="https://doi.org/10.1007%2Fs002280050490" class="external text external">10.1007/s002280050490</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9754991  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9754991'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9754991" class="external text external">9754991</a>.</cite></span></li><li id="cite_note-Dinnendahl-6"> <span id="mw-reference-text-cite_note-Dinnendahl-6" class="mw-reference-text"><cite id="CITEREFDinnendahlFricke1998" class="citation book cs1">Dinnendahl V, Fricke U, eds. (1998). <i>Arzneistoff-Profile</i> (in German). <b>10</b> (13 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN<span>&nbsp;</span><bdi>978-3-7741-9846-3</bdi>.</cite></span></li><li id="cite_note-EMA-7"> <span id="mw-reference-text-cite_note-EMA-7" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000132/WC500034731.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000132/WC500034731.pdf'" tppabs="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000132/WC500034731.pdf" class="external text external">"Tasmar: EPAR – Product Information"</a> <span class="cs1-format">(PDF)</span>. European Medicines Agency. 3 August 2016.</cite></span></li><li id="cite_note-pmid17909307-8"> <span id="mw-reference-text-cite_note-pmid17909307-8" class="mw-reference-text"><cite id="CITEREFOlanowWatkins2007" class="citation journal cs1">Olanow CW, Watkins PB (2007). "Tolcapone: an efficacy and safety review (2007)". <i>Clinical Neuropharmacology</i>. <b>30</b> (5): 287–94. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2Fwnf.0b013e318038d2b6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2Fwnf.0b013e318038d2b6'" tppabs="https://doi.org/10.1097%2Fwnf.0b013e318038d2b6" class="external text external">10.1097/wnf.0b013e318038d2b6</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17909307  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17909307'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17909307" class="external text external">17909307</a>.</cite></span></li><li id="cite_note-ncbi_b-9"> <span id="mw-reference-text-cite_note-ncbi_b-9" class="mw-reference-text"><cite id="CITEREFTruong2009" class="citation journal cs1">Truong DD (2009). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685232  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685232'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685232" class="external text external">"Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease"</a>. <i>Clinical Interventions in Aging</i>. <b>4</b>: 109–13. doi:<a href="javascript:if(confirm('https://doi.org/10.2147%2FCIA.S3787  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2147%2FCIA.S3787'" tppabs="https://doi.org/10.2147%2FCIA.S3787" class="external text external">10.2147/CIA.S3787</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685232  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685232'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685232" class="external text external">2685232</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19503773  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19503773'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19503773" class="external text external">19503773</a>.</cite></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite id="CITEREFDeleuNorthwayHanssens2002" class="citation journal cs1">Deleu D, Northway MG, Hanssens Y (2002). "Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease". <i>Clinical Pharmacokinetics</i>. <b>41</b> (4): 261–309. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003088-200241040-00003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003088-200241040-00003'" tppabs="https://doi.org/10.2165%2F00003088-200241040-00003" class="external text external">10.2165/00003088-200241040-00003</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11978145  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11978145'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11978145" class="external text external">11978145</a>.</cite></span></li><li id="cite_note-ncbi-11"> <span id="mw-reference-text-cite_note-ncbi-11" class="mw-reference-text"><cite id="CITEREFJorgaFottelerHeizmannGasser1999" class="citation journal cs1">Jorga K, Fotteler B, Heizmann P, Gasser R (October 1999). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014389  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014389'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014389" class="external text external">"Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase"</a>. <i>British Journal of Clinical Pharmacology</i>. <b>48</b> (4): 513–20. doi:<a href="javascript:if(confirm('https://doi.org/10.1046%2Fj.1365-2125.1999.00036.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1046%2Fj.1365-2125.1999.00036.x'" tppabs="https://doi.org/10.1046%2Fj.1365-2125.1999.00036.x" class="external text external">10.1046/j.1365-2125.1999.00036.x</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014389  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014389'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014389" class="external text external">2014389</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10583021  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10583021'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10583021" class="external text external">10583021</a>.</cite></span></li><li id="cite_note-12"> <span id="mw-reference-text-cite_note-12" class="mw-reference-text"><cite id="CITEREFForsbergHuotariSavolainenMännistö2005" class="citation journal cs1">Forsberg MM, Huotari M, Savolainen J, Männistö PT (April 2005). "The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration". <i>European Journal of Pharmaceutical Sciences</i>. <b>24</b> (5): 503–11. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ejps.2005.01.005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ejps.2005.01.005'" tppabs="https://doi.org/10.1016%2Fj.ejps.2005.01.005" class="external text external">10.1016/j.ejps.2005.01.005</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15784340  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15784340'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15784340" class="external text external">15784340</a>.</cite></span></li><li id="cite_note-13"> <span id="mw-reference-text-cite_note-13" class="mw-reference-text"><cite id="CITEREFNovaroliBouchard_DoulakasReistRolando2006" class="citation journal cs1">Novaroli L, Bouchard Doulakas G, Reist M, Rolando B, Fruttero R, Gasco A, Carrupt PA (2006). "The Lipophilicity Behavior of Three Catechol-O-methyltransferase (COMT) Inhibitors and Simple Analogues". <i>Helvetica Chimica Acta</i>. <b>89</b> (1): 144–152. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fhlca.200690007  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fhlca.200690007'" tppabs="https://doi.org/10.1002%2Fhlca.200690007" class="external text external">10.1002/hlca.200690007</a>.</cite></span></li><li id="cite_note-Manikumar-14"> <span id="mw-reference-text-cite_note-Manikumar-14" class="mw-reference-text"><cite id="CITEREFManikumarJinRehder2008" class="citation journal cs1">Manikumar G, Jin C, Rehder KS (2008). "Convenient Synthesis of Tolcapone, a Selective Catechol‐O‐methyltransferase Inhibitor". <i>Synthetic Communications</i>. <b>38</b> (5): 810–815. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F00397910701821077  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F00397910701821077'" tppabs="https://doi.org/10.1080%2F00397910701821077" class="external text external">10.1080/00397910701821077</a>.</cite></span></li><li id="cite_note-apps-15"> <span id="mw-reference-text-cite_note-apps-15" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://apps.who.int/medicinedocs/en/d/Js2203e/2.59.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://apps.who.int/medicinedocs/en/d/Js2203e/2.59.html'" tppabs="http://apps.who.int/medicinedocs/en/d/Js2203e/2.59.html" class="external text external">"2001 Pharmaceuticals: Restrictions in Use and Availability"</a>. World Health Organization<span class="reference-accessdate">. Retrieved <span class="nowrap">2012-10-31</span></span>.</cite></span></li><li id="cite_note-EMEA/474722/2009-16"> <span id="mw-reference-text-cite_note-EMEA/474722/2009-16" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000132/WC500034729.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000132/WC500034729.pdf'" tppabs="http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000132/WC500034729.pdf" class="external text external">"Tasmar tolcapone EPAR summary for the public"</a> <span class="cs1-format">(PDF)</span>. European Medicine Agency<span class="reference-accessdate">. Retrieved <span class="nowrap">2012-10-31</span></span>.</cite></span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text"><cite id="CITEREFPress_Office" class="citation web cs1">Press Office, U.S. Department of Health and Human Services. <a href="javascript:if(confirm('http://scienceblog.com/community/older/archives/M/1/fda0533.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://scienceblog.com/community/older/archives/M/1/fda0533.htm'" tppabs="http://scienceblog.com/community/older/archives/M/1/fda0533.htm" class="external text external">"FDA Talk Paper"</a>. <i>New Warnings for Parkinson's Drug, Tasmar</i>. Food and Drug Administration.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=413913  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=413913'" tppabs="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=413913" class="external text external">orphan drug status for tolcapone</a></span></li><li id="cite_note-19"> <span id="mw-reference-text-cite_note-19" class="mw-reference-text"><cite id="CITEREFReigVenturaSalvadóGámez2015" class="citation journal cs1">Reig N, Ventura S, Salvadó M, Gámez J, Insa R (2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642128  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642128'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642128" class="external text external">"SOM0226, a repositioned compound for the treatment of TTR amyloidosis"</a>. <i>Orphanet J Rare Dis</i>. <b>10</b> (Suppl 1): P9. doi:<a href="javascript:if(confirm('https://doi.org/10.1186%2F1750-1172-10-s1-p9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1186%2F1750-1172-10-s1-p9'" tppabs="https://doi.org/10.1186%2F1750-1172-10-s1-p9" class="external text external">10.1186/1750-1172-10-s1-p9</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642128  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642128'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642128" class="external text external">4642128</a></span>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><a href="javascript:if(confirm('http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=TCW  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=TCW'" tppabs="http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=TCW" class="external text external">Tolcapone bound to proteins</a> in the PDB</li></ul>
<p>
<br></p>
<div role="navigation" class="navbox" aria-labelledby="Antiparkinson_agents_(N04)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Antiparkinson_agents_(N04)" style="font-size:114%;margin:0 4em">Antiparkinson agents (N04)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Dopaminergics</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Dopamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dopamine" title="Dopamine">DA</a> precursors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="L-DOPA.htm" tppabs="https://ptable.com/wiki/compounds/A/L-DOPA" title="L-DOPA">Levodopa</a><sup>#</sup></li>
<li>Melevodopa</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">DA receptor agonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Apomorphine.htm" tppabs="https://ptable.com/wiki/compounds/A/Apomorphine" title="Apomorphine">Apomorphine</a></li>
<li><a href="Bromocriptine.htm" tppabs="https://ptable.com/wiki/compounds/A/Bromocriptine" title="Bromocriptine">Bromocriptine</a></li>
<li><a href="Cabergoline.htm" tppabs="https://ptable.com/wiki/compounds/A/Cabergoline" title="Cabergoline">Cabergoline</a></li>
<li>Dihydroergocryptine</li>
<li><a href="Lisuride.htm" tppabs="https://ptable.com/wiki/compounds/A/Lisuride" title="Lisuride">Lisuride</a></li>
<li><a href="Pergolide.htm" tppabs="https://ptable.com/wiki/compounds/A/Pergolide" title="Pergolide">Pergolide</a></li>
<li>Piribedil</li>
<li>Pramipexole</li>
<li><a href="Ropinirole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ropinirole" title="Ropinirole">Ropinirole</a></li>
<li>Rotigotine</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">MAO-B inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Rasagiline.htm" tppabs="https://ptable.com/wiki/compounds/A/Rasagiline" title="Rasagiline">Rasagiline</a></li>
<li>Safinamide</li>
<li><a href="Selegiline.htm" tppabs="https://ptable.com/wiki/compounds/A/Selegiline" title="Selegiline">Selegiline</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">COMT inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Entacapone.htm" tppabs="https://ptable.com/wiki/compounds/A/Entacapone" title="Entacapone">Entacapone</a></li>
<li>Opicapone</li>
<li><a href="Tolcapone.htm" tppabs="https://ptable.com/wiki/compounds/A/Tolcapone" title="Tolcapone">Tolcapone</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">AAAD inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Benserazide</li>
<li><a href="Carbidopa.htm" tppabs="https://ptable.com/wiki/compounds/A/Carbidopa" title="Carbidopa">Carbidopa</a><sup>#</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Anticholinergics</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Benzatropine.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzatropine" title="Benzatropine">Benzatropine</a></li>
<li><a href="Biperiden.htm" tppabs="https://ptable.com/wiki/compounds/A/Biperiden" title="Biperiden">Biperiden</a><sup>#</sup></li>
<li>Bornaprine</li>
<li>Chlorphenoxamine</li>
<li><a href="Cycrimine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cycrimine" title="Cycrimine">Cycrimine</a></li>
<li>Dexetimide</li>
<li><a href="Diphenhydramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Diphenhydramine" title="Diphenhydramine">Diphenhydramine</a></li>
<li>Etanautine</li>
<li>Etybenzatropine</li>
<li>Mazaticol</li>
<li><a href="Metixene.htm" tppabs="https://ptable.com/wiki/compounds/A/Metixene" title="Metixene">Metixene</a></li>
<li><a href="Orphenadrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Orphenadrine" title="Orphenadrine">Orphenadrine</a></li>
<li>Phenglutarimide</li>
<li>Piroheptine</li>
<li><a href="Procyclidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Procyclidine" title="Procyclidine">Procyclidine</a></li>
<li><a href="Profenamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Profenamine" title="Profenamine">Profenamine</a></li>
<li><a href="Trihexyphenidyl.htm" tppabs="https://ptable.com/wiki/compounds/A/Trihexyphenidyl" title="Trihexyphenidyl">Trihexyphenidyl</a></li>
<li>Tropatepine</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Amantadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amantadine" title="Amantadine">Amantadine</a></li>
<li>Budipine</li>
<li><a href="Xanthine.htm" tppabs="https://ptable.com/wiki/compounds/A/Xanthine" title="Xanthine">Methylxanthines</a> (e.g., <a href="Caffeine.htm" tppabs="https://ptable.com/wiki/compounds/A/Caffeine" title="Caffeine">caffeine</a>)</li>
<li><a href="Rimantadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Rimantadine" title="Rimantadine">Rimantadine</a></li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-even hlist" style="width:100%;padding:0px"><div style="padding:0em 0.25em"><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Monoamine_metabolism_modulators" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Monoamine_metabolism_modulators" style="font-size:114%;margin:0 4em">Monoamine metabolism modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Non-specific</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:4em;;text-align:center;"><abbr>AAAD</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Substrates→Products:</b> <a href="L-DOPA.htm" tppabs="https://ptable.com/wiki/compounds/A/L-DOPA" title="L-DOPA"><small>L</small>-DOPA (levodopa)</a>→<a href="Dopamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dopamine" title="Dopamine">Dopamine</a></li>
<li><a href="5-Hydroxytryptophan.htm" tppabs="https://ptable.com/wiki/compounds/A/5-HTP" title="5-HTP" class="mw-redirect">5-HTP</a>→<a href="Serotonin.htm" tppabs="https://ptable.com/wiki/compounds/A/Serotonin" title="Serotonin">Serotonin</a></li>
<li><small>L</small>-Histidine→<a href="Histamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Histamine" title="Histamine">Histamine</a></li>
<li><a href="Phenylalanine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenylalanine" title="Phenylalanine">Phenylalanine</a>→<a href="Phenethylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenethylamine" title="Phenethylamine">Phenethylamine</a></li>
<li><small>L</small>-Tyrosine→<a href="Tyramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Tyramine" title="Tyramine">Tyramine</a></li>
<li><a href="Tryptophan.htm" tppabs="https://ptable.com/wiki/compounds/A/Tryptophan" title="Tryptophan">Tryptophan</a>→<a href="Tryptamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Tryptamine" title="Tryptamine">Tryptamine</a></li></ul>

<ul><li><b>Inhibitors:</b> Benserazide</li>
<li><a href="Carbidopa.htm" tppabs="https://ptable.com/wiki/compounds/A/Carbidopa" title="Carbidopa">Carbidopa</a></li>
<li>DFMD</li>
<li><a href="Genistein.htm" tppabs="https://ptable.com/wiki/compounds/A/Genistein" title="Genistein">Genistein</a></li>
<li><a href="Methyldopa.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyldopa" title="Methyldopa">Methyldopa</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:4em;;text-align:center;"><abbr>MAO</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><td colspan="2" class="navbox-list navbox-even" style="width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Substrates→Products (with <abbr>ALDH</abbr>/<abbr>ALR</abbr>):</b> <a href="Epinephrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Epinephrine" title="Epinephrine" class="mw-redirect">Epinephrine (adrenaline)</a>→DHMA</li>
<li>Metanephrine→MHPG/<a href="Vanillylmandelic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Vanillylmandelic_acid" title="Vanillylmandelic acid">VMA</a></li>
<li>Norepinephrine (noradrenaline)→DHMA</li>
<li>Normetanephrine→MHPG/<a href="Vanillylmandelic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Vanillylmandelic_acid" title="Vanillylmandelic acid">VMA</a></li>
<li><a href="Dopamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dopamine" title="Dopamine">Dopamine</a>→<a href="3,4-Dihydroxyphenylacetic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/3%2C4-Dihydroxyphenylacetic_acid" title="3,4-Dihydroxyphenylacetic acid">DOPAC</a></li>
<li><a href="3-Methoxytyramine.htm" tppabs="https://ptable.com/wiki/compounds/A/3-Methoxytyramine" title="3-Methoxytyramine">3-Methoxytyramine</a>→<a href="Homovanillic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Homovanillic_acid" title="Homovanillic acid">HVA</a></li>
<li><a href="Serotonin.htm" tppabs="https://ptable.com/wiki/compounds/A/Serotonin" title="Serotonin">Serotonin</a>→<a href="5-Hydroxyindoleacetic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/5-Hydroxyindoleacetic_acid" title="5-Hydroxyindoleacetic acid">5-HIAA</a></li></ul>

<ul><li><b>Inhibitors:</b> <i>Non-selective:</i> Benmoxin</li>
<li>Caroxazone</li>
<li>Echinopsidine</li>
<li><a href="Furazolidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Furazolidone" title="Furazolidone">Furazolidone</a></li>
<li>Guineesine</li>
<li><a href="Hydralazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydralazine" title="Hydralazine">Hydralazine</a></li>
<li>Indantadol</li>
<li>Iproclozide</li>
<li><a href="Iproniazid.htm" tppabs="https://ptable.com/wiki/compounds/A/Iproniazid" title="Iproniazid">Iproniazid</a></li>
<li><a href="Isocarboxazid.htm" tppabs="https://ptable.com/wiki/compounds/A/Isocarboxazid" title="Isocarboxazid">Isocarboxazid</a></li>
<li><a href="Isoniazid.htm" tppabs="https://ptable.com/wiki/compounds/A/Isoniazid" title="Isoniazid">Isoniazid</a></li>
<li><a href="Linezolid.htm" tppabs="https://ptable.com/wiki/compounds/A/Linezolid" title="Linezolid">Linezolid</a></li>
<li>Mebanazine</li>
<li>Metfendrazine</li>
<li><a href="Nialamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nialamide" title="Nialamide">Nialamide</a></li>
<li>Octamoxin</li>
<li>Paraxazone</li>
<li><a href="Phenelzine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenelzine" title="Phenelzine">Phenelzine</a></li>
<li>Pheniprazine</li>
<li>Phenoxypropazine</li>
<li>Pivhydrazine</li>
<li><a href="Procarbazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Procarbazine" title="Procarbazine">Procarbazine</a></li>
<li>Safrazine</li>
<li><a href="Tranylcypromine.htm" tppabs="https://ptable.com/wiki/compounds/A/Tranylcypromine" title="Tranylcypromine">Tranylcypromine</a></li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Inhibitors:</b> <i>MAO-A-selective:</i> Amiflamine</li>
<li>Bazinaprine</li>
<li>Befloxatone</li>
<li>Brofaromine</li>
<li>Cimoxatone</li>
<li><a href="Clorgiline.htm" tppabs="https://ptable.com/wiki/compounds/A/Clorgiline" title="Clorgiline">Clorgiline</a></li>
<li>CX157 (Tyrima)</li>
<li>Eprobemide</li>
<li>Esuprone</li>
<li><a href="Harmala_alkaloid.htm" tppabs="https://ptable.com/wiki/compounds/A/Harmala_alkaloid" title="Harmala alkaloid">Harmala alkaloids</a> (e.g., <a href="Harmine.htm" tppabs="https://ptable.com/wiki/compounds/A/Harmine" title="Harmine">harmine</a>, <a href="Harmaline.htm" tppabs="https://ptable.com/wiki/compounds/A/Harmaline" title="Harmaline">harmaline</a>, harman, norharman, tetrahydroharmine)</li>
<li>Methylene blue</li>
<li>Metralindole</li>
<li><a href="Minaprine.htm" tppabs="https://ptable.com/wiki/compounds/A/Minaprine" title="Minaprine">Minaprine</a></li>
<li><a href="Moclobemide.htm" tppabs="https://ptable.com/wiki/compounds/A/Moclobemide" title="Moclobemide">Moclobemide</a></li>
<li>Pirlindole</li>
<li>Sercloremine</li>
<li>Tetrindole</li>
<li>Toloxatone</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-even" style="width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Inhibitors:</b> <i>MAO-B selective:</i> <span class="new">Adarigiline</span></li>
<li>Almoxatone</li>
<li><small>D</small>-Deprenyl</li>
<li><a href="Ethanol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethanol" title="Ethanol">Ethanol</a></li>
<li>Ladostigil</li>
<li>Lazabemide</li>
<li>Milacemide</li>
<li>Mofegiline</li>
<li><a href="Nicotine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nicotine" title="Nicotine">Nicotine</a></li>
<li><a href="Pargyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Pargyline" title="Pargyline">Pargyline</a><sup>‡</sup></li>
<li><a href="Rasagiline.htm" tppabs="https://ptable.com/wiki/compounds/A/Rasagiline" title="Rasagiline">Rasagiline</a></li>
<li>Safinamide</li>
<li><a href="Selegiline.htm" tppabs="https://ptable.com/wiki/compounds/A/Selegiline" title="Selegiline">Selegiline (<small>L</small>-Deprenyl)</a></li>
<li><span class="new">Sembragiline</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Phenethylamines<br><small>(<a href="Dopamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dopamine" title="Dopamine">dopamine</a>, <a href="Epinephrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Epinephrine" title="Epinephrine" class="mw-redirect">epinephrine</a>,<br>norepinephrine)</small></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:4em;;text-align:center;"><abbr>PAH</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Substrates→Products:</b> <a href="Phenylalanine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenylalanine" title="Phenylalanine">Phenylalanine</a>→<a href="Tyrosine.htm" tppabs="https://ptable.com/wiki/compounds/A/Tyrosine" title="Tyrosine">Tyrosine</a></li></ul>

<ul><li><b>Inhibitors:</b> 3,4-Dihydroxystyrene</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:4em;;text-align:center;"><abbr>TH</abbr></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Substrates→Products:</b> <a href="Tyrosine.htm" tppabs="https://ptable.com/wiki/compounds/A/Tyrosine" title="Tyrosine">Tyrosine</a>→<a href="L-DOPA.htm" tppabs="https://ptable.com/wiki/compounds/A/L-DOPA" title="L-DOPA"><small>L</small>-DOPA (levodopa)</a></li></ul>

<ul><li><b>Inhibitors:</b> 2-Hydroxyestradiol</li>
<li>2-Hydroxyestrone</li>
<li>3-Iodotyrosine</li>
<li>Aquayamycin</li>
<li>Bulbocapnine</li>
<li><a href="Metirosine.htm" tppabs="https://ptable.com/wiki/compounds/A/Metirosine" title="Metirosine">Metirosine</a></li>
<li>Oudenone</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:4em;;text-align:center;"><abbr>DBH</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Substrates→Products:</b> <a href="Dopamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dopamine" title="Dopamine">Dopamine</a>→Norepinephrine (Noradrenaline)</li></ul>

<ul><li><b>Inhibitors:</b> Bupicomide</li>
<li><a href="Disulfiram.htm" tppabs="https://ptable.com/wiki/compounds/A/Disulfiram" title="Disulfiram">Disulfiram</a></li>
<li>Dopastin</li>
<li><a href="Fusaric_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Fusaric_acid" title="Fusaric acid">Fusaric acid</a></li>
<li>Nepicastat</li>
<li>Phenopicolinic acid</li>
<li><a href="Tropolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Tropolone" title="Tropolone">Tropolone</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:4em;;text-align:center;"><abbr>PNMT</abbr></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Substrates→Products:</b> Norepinephrine (noradrenaline)→<a href="Epinephrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Epinephrine" title="Epinephrine" class="mw-redirect">Epinephrine (adrenaline)</a></li></ul>

<ul><li><b>Inhibitors:</b> <span class="new">CGS-19281A</span></li>
<li><span class="new">SKF-64139</span></li>
<li><span class="new">SKF-7698</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:4em;;text-align:center;"><abbr>COMT</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Substrates→Products:</b> <a href="Dopamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dopamine" title="Dopamine">Dopamine</a>→<a href="3-Methoxytyramine.htm" tppabs="https://ptable.com/wiki/compounds/A/3-Methoxytyramine" title="3-Methoxytyramine">3-Methoxytyramine</a></li>
<li><a href="3,4-Dihydroxyphenylacetic_acid-1.htm" tppabs="https://ptable.com/wiki/compounds/A/DOPAC" title="DOPAC" class="mw-redirect">DOPAC</a>→<a href="Homovanillic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Homovanillic_acid" title="Homovanillic acid">Homovanillic acid</a></li>
<li>Norepinephrine→Normetanephrine</li>
<li><a href="Epinephrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Epinephrine" title="Epinephrine" class="mw-redirect">Epinephrine</a>→Metanephrine</li>
<li><a href="Dihydroxyphenylethylene_glycol.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydroxyphenylethylene_glycol" title="Dihydroxyphenylethylene glycol">DOPEG</a>→MOPEG</li>
<li>DOMA→<a href="Vanillylmandelic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Vanillylmandelic_acid" title="Vanillylmandelic acid">VMA</a></li>
<li>2-Hydroxyestradiol→<a href="2-Methoxyestradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/2-Methoxyestradiol" title="2-Methoxyestradiol">2-Methoxyestradiol</a></li>
<li>2-Hydroxyestrone→2-Methoxyestrone</li>
<li>4-Hydroxyestradiol→4-Methoxyestradiol</li>
<li>4-Hydroxyestrone→4-Methoxyestrone</li></ul>

<ul><li><b>Inhibitors:</b> 2-Hydroxyestradiol</li>
<li>2-Hydroxyestrone</li>
<li><a href="Entacapone.htm" tppabs="https://ptable.com/wiki/compounds/A/Entacapone" title="Entacapone">Entacapone</a></li>
<li><span class="new">Neluxicapone</span></li>
<li><a href="Nitecapone.htm" tppabs="https://ptable.com/wiki/compounds/A/Nitecapone" title="Nitecapone">Nitecapone</a></li>
<li>Opicapone</li>
<li><a href="Quinalizarin.htm" tppabs="https://ptable.com/wiki/compounds/A/Quinalizarin" title="Quinalizarin">Quinalizarin</a></li>
<li><a href="Tolcapone.htm" tppabs="https://ptable.com/wiki/compounds/A/Tolcapone" title="Tolcapone">Tolcapone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Tryptamines<br><small>(<a href="Serotonin.htm" tppabs="https://ptable.com/wiki/compounds/A/Serotonin" title="Serotonin">serotonin</a>, <a href="Melatonin.htm" tppabs="https://ptable.com/wiki/compounds/A/Melatonin" title="Melatonin">melatonin</a>)</small></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:4em;;text-align:center;"><abbr>TPH</abbr></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Substrates→Products:</b> <a href="Tryptophan.htm" tppabs="https://ptable.com/wiki/compounds/A/Tryptophan" title="Tryptophan">Tryptophan</a>→<a href="5-Hydroxytryptophan.htm" tppabs="https://ptable.com/wiki/compounds/A/5-HTP" title="5-HTP" class="mw-redirect">5-HTP</a></li></ul>

<ul><li><b>Inhibitors:</b> AGN-2979</li>
<li><a href="Fenclonine.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenclonine" title="Fenclonine">Fenclonine (PCPA)</a></li>
<li>Telotristat ethyl</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:4em;;text-align:center;"><abbr>AANAT</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Substrates→Products:</b> <a href="Serotonin.htm" tppabs="https://ptable.com/wiki/compounds/A/Serotonin" title="Serotonin">Serotonin</a>→<a href="N-Acetylserotonin.htm" tppabs="https://ptable.com/wiki/compounds/A/N-Acetylserotonin" title="N-Acetylserotonin">N-Acetylserotonin</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:4em;;text-align:center;"><abbr>ASMT</abbr></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Substrates→Products:</b> <a href="N-Acetylserotonin.htm" tppabs="https://ptable.com/wiki/compounds/A/N-Acetylserotonin" title="N-Acetylserotonin">N-Acetylserotonin</a>→<a href="Melatonin.htm" tppabs="https://ptable.com/wiki/compounds/A/Melatonin" title="Melatonin">Melatonin</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="Histamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Histamine" title="Histamine">Histamine</a></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:4em;;text-align:center;"><abbr>HDC</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Substrates→Products:</b> <small>L</small>-Histidine→<a href="Histamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Histamine" title="Histamine">Histamine</a></li></ul>

<ul><li><b>Inhibitors:</b> <a href="Catechin.htm" tppabs="https://ptable.com/wiki/compounds/A/(%2B)-Catechin" title="(+)-Catechin" class="mw-redirect">Catechin</a></li>
<li>Alpha-Fluoromethylhistidine</li>
<li>Histidine methyl ester</li>
<li>Meciadanol</li>
<li><a href="Naringenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Naringenin" title="Naringenin">Naringenin</a></li>
<li>Tritoqualine</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:4em;;text-align:center;"><abbr>HNMT</abbr></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Substrates→Products:</b> <a href="Histamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Histamine" title="Histamine">Histamine</a>→<span class="new">N-Methylhistamine</span></li></ul>

<ul><li><b>Inhibitors:</b> <a href="Amodiaquine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amodiaquine" title="Amodiaquine">Amodiaquine</a></li>
<li><a href="Diphenhydramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Diphenhydramine" title="Diphenhydramine">Diphenhydramine</a></li>
<li><a href="Harmaline.htm" tppabs="https://ptable.com/wiki/compounds/A/Harmaline" title="Harmaline">Harmaline</a></li>
<li><span class="new">Metoprine</span></li>
<li><a href="Quinacrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Quinacrine" title="Quinacrine" class="mw-redirect">Quinacrine</a></li>
<li>SKF-91488</li>
<li><a href="Tacrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrine" title="Tacrine">Tacrine</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:4em;;text-align:center;"><abbr>DAO</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Substrates→Products:</b> <a href="Histamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Histamine" title="Histamine">Histamine</a>→<span class="new">Imidazole acetic acid</span></li></ul>

<ul><li><b>Inhibitors:</b> <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Pimagedine  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Pimagedine'" tppabs="https://ptable.com/wiki/compounds/A/Pimagedine" title="Pimagedine">Pimagedine (aminoguanidine)</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div><small><i><b>See also:</b> Receptor/signaling modulators • Adrenergics • Dopaminergics • Melatonergics • Serotonergics • Monoamine reuptake inhibitors • Monoamine releasing agents • Monoamine neurotoxins</i></small></div></td></tr></tbody></table></div>






<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>